A Phase 1 Dose-Escalation Study of LY2382770, a TGF-beta Monoclonal Antibody, in Patients with Metastatic Cancer

Trial Profile

A Phase 1 Dose-Escalation Study of LY2382770, a TGF-beta Monoclonal Antibody, in Patients with Metastatic Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 May 2010

At a glance

  • Drugs LY 2382770 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 04 May 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top